Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wolff

Showing results (871-880 of 973) with videos related to

Pageof 98
Sort By:
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|November 22, 2020
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinomaDongguang Wei, Mohamed M Zaid, Matthew H Katz, et al.
Oncotargets and Therapy|March 2, 2016
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinomaAhmed O Kaseb, Jeffrey S Morris, Michiko Iwasaki, et al.
Klinische Padiatrie|May 3, 2016
Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents - Recommendations of the GPOH-NPC Study GroupU Kontny, S Franzen, U Behrends, et al.
Annals of Surgical Oncology|October 17, 2018
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaPat Gulhati, Laura Prakash, Matthew H G Katz, et al.
Gastroenterology|April 4, 2015
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular CarcinomaManal M Hassan, Reham Abdel-Wahab, Ahmed Kaseb, et al.
Annals of Surgical Oncology|February 18, 2010
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiationMatthew H G Katz, Gauri R Varadhachary, Jason B Fleming, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2010
A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivityMarkus A Schirmer, Jürgen Brockmöller, Margret Rave-Fränk, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2002
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Christopher H Crane, James L Abbruzzese, Douglas B Evans, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.
Pageof 98

Showing results (871-880 of 973) with videos related to

Sort By:
Pageof 98
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|November 22, 2020
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinomaDongguang Wei, Mohamed M Zaid, Matthew H Katz, et al.
Oncotargets and Therapy|March 2, 2016
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinomaAhmed O Kaseb, Jeffrey S Morris, Michiko Iwasaki, et al.
Klinische Padiatrie|May 3, 2016
Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents - Recommendations of the GPOH-NPC Study GroupU Kontny, S Franzen, U Behrends, et al.
Annals of Surgical Oncology|October 17, 2018
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaPat Gulhati, Laura Prakash, Matthew H G Katz, et al.
Gastroenterology|April 4, 2015
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular CarcinomaManal M Hassan, Reham Abdel-Wahab, Ahmed Kaseb, et al.
Annals of Surgical Oncology|February 18, 2010
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiationMatthew H G Katz, Gauri R Varadhachary, Jason B Fleming, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2010
A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivityMarkus A Schirmer, Jürgen Brockmöller, Margret Rave-Fränk, et al.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2002
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Christopher H Crane, James L Abbruzzese, Douglas B Evans, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.
Pageof 98